
A new study conducted by researchers at Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH) in the United States has found that the Bacillus Calmette-Guerin (BCG) vaccine, which is commonly used to prevent tuberculosis, is associated with a reduced risk of Alzheimer's disease and related dementias. The study followed 6,467 individuals diagnosed with non-muscle-invasive bladder cancer for up to 15 years, comparing the outcomes of those who received BCG vaccine treatment (3,388 patients) with a control group (3,079 patients). The study discovered that the incidence of Alzheimer's disease and related dementias was 20% lower in the BCG vaccine group. The protective association was even greater among patients aged 70 years or older. Additionally, the study found that treatment with the BCG vaccine was associated with a 25% lower risk of death. The study now focuses on evaluating the potential benefits of BCG vaccination in older adults in Alzheimer's disease-related clinical trials. It is believed that if a causal link is established, it will be important to understand the mechanisms through which the BCG vaccine affects the immune system to provide these protective effects.
Like
Save
Share